RS59969B1 - Čvrsti farmaceutski dozni oblik - Google Patents

Čvrsti farmaceutski dozni oblik

Info

Publication number
RS59969B1
RS59969B1 RS20181262A RSP20181262A RS59969B1 RS 59969 B1 RS59969 B1 RS 59969B1 RS 20181262 A RS20181262 A RS 20181262A RS P20181262 A RSP20181262 A RS P20181262A RS 59969 B1 RS59969 B1 RS 59969B1
Authority
RS
Serbia
Prior art keywords
dosage form
pharmaceutically acceptable
pharmaceutical dosage
solid pharmaceutical
soluble polymer
Prior art date
Application number
RS20181262A
Other languages
English (en)
Inventor
Jörg Rosenberg
Ulrich Reinhold
Bernd Liepold
Gunther Berndl
Jörg Breitenbach
Laman Alani
Soumojeet Ghosh
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34217089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS59969(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of RS20181262A1 publication Critical patent/RS20181262A1/sr
Publication of RS59969B1 publication Critical patent/RS59969B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>Opisan je čvrsti farmaceutski dozni oblik za obezbeđivanje poboljšane oralne biodostupnosti inhibitora HIV proteaze. Naročito, dozni oblici sadrže čvrste disperzije bar jednog inhibitora HIV proteaze i bar jednog farmaceutski prihvatljivog vodorastvoronog polimera i bar jednog farmaceutski prihvatljivog površinski aktivnog sredstva, pomenuti farmaceutski prihvatljiv vodorastvorni polimer ima Tg od bar oko 50°C. Poželjno, farmaceutski prihvatljivo površinski aktivno sredstvo ima HLB vrednost od oko 4 do oko 10.</p>
RS20181262A 2003-08-28 2004-08-23 Čvrsti farmaceutski dozni oblik RS59969B1 (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/650,178 US20050048112A1 (en) 2003-08-28 2003-08-28 Solid pharmaceutical dosage form

Publications (2)

Publication Number Publication Date
RS20181262A1 RS20181262A1 (sr) 2019-02-28
RS59969B1 true RS59969B1 (sr) 2020-03-31

Family

ID=34217089

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20181262A RS59969B1 (sr) 2003-08-28 2004-08-23 Čvrsti farmaceutski dozni oblik
YU20060140A RS57663B1 (sr) 2003-08-28 2004-08-23 Čvrsti farmaceutski dozni oblik

Family Applications After (1)

Application Number Title Priority Date Filing Date
YU20060140A RS57663B1 (sr) 2003-08-28 2004-08-23 Čvrsti farmaceutski dozni oblik

Country Status (31)

Country Link
US (1) US20050048112A1 (sr)
EP (6) EP2258344B1 (sr)
JP (6) JP4815348B2 (sr)
KR (5) KR101457967B1 (sr)
CN (5) CN102772380B (sr)
AT (1) ATE516017T1 (sr)
AU (3) AU2004283087C1 (sr)
CA (2) CA2689639C (sr)
CR (3) CR8256A (sr)
CY (5) CY1111981T1 (sr)
DK (5) DK2258344T3 (sr)
EA (4) EA020992B1 (sr)
EC (1) ECSP066397A (sr)
ES (5) ES2608720T3 (sr)
HK (4) HK1094766A1 (sr)
HR (1) HRP20110555T1 (sr)
HU (3) HUE038792T2 (sr)
IL (3) IL173939A (sr)
ME (2) ME00130B (sr)
MX (2) MXPA06002346A (sr)
NO (3) NO330282B1 (sr)
NZ (2) NZ579622A (sr)
PL (5) PL2258345T3 (sr)
PT (5) PT1663183E (sr)
RS (2) RS59969B1 (sr)
SG (3) SG179401A1 (sr)
SI (5) SI2258346T1 (sr)
TW (1) TWI342221B (sr)
UA (1) UA85564C2 (sr)
WO (1) WO2005039551A2 (sr)
ZA (3) ZA200801362B (sr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359945C (en) * 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
AU2012202831B2 (en) * 2005-02-23 2015-01-22 Abbvie Inc. A solid pharmaceutical dosage formulation
KR20070025070A (ko) * 2005-08-31 2007-03-08 주식회사 대웅제약 시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법
AU2006325404B2 (en) * 2005-12-14 2012-03-01 Cipla Limited Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
KR20080089344A (ko) * 2005-12-14 2008-10-06 에프. 호프만-라 로슈 아게 Ｃ형 간염 바이러스(ｈｃｖ) 전구약물 제형
US20090136570A1 (en) * 2006-01-20 2009-05-28 Bhagwant Rege Taste-Masked Tablets and Granules
EP1832281A1 (en) * 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
CA2660374A1 (en) * 2006-08-10 2008-02-14 Cipla Limited Antiretroviral solid oral composition
WO2008067164A2 (en) 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations
ES2603617T3 (es) 2007-02-23 2017-02-28 Gilead Sciences, Inc. Moduladores de propiedades farmacocinéticas de la terapéutica
PA8809601A1 (es) * 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral
TWI583405B (zh) * 2008-02-28 2017-05-21 艾伯維有限公司 錠劑及其製備
WO2009153654A1 (en) * 2008-06-17 2009-12-23 Aurobindo Pharma Limited Solid dosage forms of antiretrovirals
UA106878C2 (uk) * 2008-10-07 2014-10-27 Астразенека Юк Лімітед Фармацевтична композиція, що містить 4-[3-(4-циклопропанкарбонілпіперазин-1-карбоніл)-4-фторбензил]-2н-фталазин-1-он або його сіль, або сольват, у твердій дисперсії з матричним полімером коповідоном
WO2010070611A1 (en) 2008-12-18 2010-06-24 Ranbaxy Laboratories Limited Atazanavir formulations
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
US20110034489A1 (en) 2009-07-31 2011-02-10 Ranbaxy Laboratories Limited Solid dosage forms of hiv protease inhibitors
WO2011013110A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Unit dosage forms of hiv protease inhibitors
BR112013007862A2 (pt) 2010-10-01 2019-09-24 Moderna Therapeutics Inc ácidos nucleicos manipulados e métodos de uso dos mesmos.
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
US20140066468A1 (en) * 2011-03-07 2014-03-06 Bandi Parthasaradhi Reddy Amorphous form of lopinavir and ritonavir mixture
EP2714683A4 (en) 2011-05-27 2014-11-05 Hetero Research Foundation RITONAVIR AMORPH CO-PRECIPITATION
JP2014521745A (ja) * 2011-08-16 2014-08-28 メルク・シャープ・アンド・ドーム・コーポレーション 安定した非晶質分散体を調製するための無機マトリックスと有機ポリマーの組み合わせの使用
EP2564832A1 (en) 2011-08-29 2013-03-06 Hexal AG Solid dosage form of HIV protease inhibitors
KR101794032B1 (ko) * 2011-09-21 2017-11-07 (주)바이오시네틱스 나노입자 제조방법
WO2013131645A1 (en) 2012-03-07 2013-09-12 Ratiopharm Gmbh Dosage form comprising non-crystalline lopinavir and crystalline ritonavir
CA2866206A1 (en) 2012-03-07 2013-09-12 Ratiopharm Gmbh Dosage form comprising lopinavir and ritonavir
CN103655571B (zh) * 2012-09-11 2016-04-20 上海星泰医药科技有限公司 一种洛匹那韦和利托那韦复方高均匀度纳米共分散体及其制备方法
US9744240B2 (en) 2012-09-27 2017-08-29 Basf Se Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer
WO2014048783A1 (en) 2012-09-27 2014-04-03 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
JP6275726B2 (ja) 2012-09-27 2018-02-07 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 少なくとも１種の水溶性ビタミンｅ誘導体および少なくとも１種の親水性ポリマーを含む、保存において安定な無塵の均質な粒子製剤
US9789063B2 (en) 2012-09-27 2017-10-17 Basf Se Storage-stable dust-free homogeneous particulate formulation
RU2505286C1 (ru) 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2543322C1 (ru) * 2013-09-19 2015-02-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2619840C1 (ru) * 2016-09-21 2017-05-18 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция для лечения ВИЧ-инфекции
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
US20190038754A1 (en) * 2017-08-07 2019-02-07 SE Tylose, USA, Inc. Pharmaceutical composition in solid extruded form
US20210361639A1 (en) * 2018-03-02 2021-11-25 The University Of Liverpool Solid compositions of actives, processes for preparing same and uses of such solid compositions
CN108186578A (zh) * 2018-03-27 2018-06-22 聊城大学 一种利托那韦固体分散体的制备方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
TWI799599B (zh) * 2019-06-06 2023-04-21 華納國際生物科技股份有限公司 醫藥或保健品自乳化固體分散組成物
CN114146061B (zh) * 2020-09-07 2023-06-30 歌礼生物科技（杭州）有限公司 包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法
US12031128B2 (en) 2021-04-07 2024-07-09 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
CN113318076B (zh) * 2021-06-02 2022-09-23 聊城大学 一种兼具增溶及抑晶效果的利托那韦固体分散体及其制备方法
CN114557967B (zh) * 2022-03-17 2023-06-02 乐普制药科技有限公司 一种利托那韦固体分散体的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525108B1 (fr) 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5542206A (en) 1994-10-11 1996-08-06 Lisch; Albert Lure and tackle stacking container
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
DE19841244A1 (de) * 1998-09-09 2000-03-16 Knoll Ag Verfahren und Vorrichtung zum Herstellen von Tabletten
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19913606A1 (de) 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
CN100418527C (zh) 1999-06-04 2008-09-17 艾博特公司 改进的药物制剂
CA2359945C (en) * 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
WO2001034118A2 (en) 1999-11-12 2001-05-17 Abbott Laboratories Solid dispersion pharmaceutical formulations
ES2284871T3 (es) 2001-06-22 2007-11-16 Pfizer Products Inc. Composiciones farmaceuticas que contienen una dispersion solida de farmaco poco soluble y un polimero potenciador de la solubilidad.
EP1469832B2 (en) * 2002-02-01 2016-10-26 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
DE10213242A1 (de) * 2002-03-25 2003-10-16 Abbott Gmbh & Co Kg Testsystem zur Evaluierung der Kompatibilität biologisch aktiver Substanzen mit Copolymeren
DE10247037A1 (de) * 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
WO2008067164A2 (en) 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations

Also Published As

Publication number Publication date
KR101457967B1 (ko) 2014-11-07
KR101132602B1 (ko) 2012-04-06
NO20131743L (no) 2006-05-29
EP2258345A3 (en) 2011-01-19
PT2942051T (pt) 2018-04-23
JP2011126898A (ja) 2011-06-30
PL2258344T3 (pl) 2013-04-30
AU2007249115A1 (en) 2008-01-10
EP1663183B9 (en) 2012-06-13
PT2258344E (pt) 2013-02-18
JP2011236232A (ja) 2011-11-24
EA201890737A2 (ru) 2018-08-31
DK2258345T3 (en) 2017-01-16
CN102772380B (zh) 2015-08-19
CA2536638A1 (en) 2005-05-06
IL254581A0 (en) 2017-11-30
JP4815348B2 (ja) 2011-11-16
JP5903413B2 (ja) 2016-04-13
IL173939A (en) 2017-03-30
CY1120138T1 (el) 2018-12-12
EP2942051A1 (en) 2015-11-11
SI2942051T1 (en) 2018-06-29
NZ579622A (en) 2011-01-28
IL207260A (en) 2017-10-31
MX358033B (es) 2018-08-02
DK2258344T3 (da) 2013-01-02
ZA200601718B (en) 2009-11-25
PL2942051T3 (pl) 2018-07-31
EA020992B1 (ru) 2015-03-31
KR20120054666A (ko) 2012-05-30
EP2258346A3 (en) 2011-01-19
SI2258344T1 (sl) 2013-03-29
MEP17608A (en) 2010-06-10
EP1663183A2 (en) 2006-06-07
CY1113596T1 (el) 2016-06-22
KR20150044031A (ko) 2015-04-23
RS20181262A1 (sr) 2019-02-28
CN105106104A (zh) 2015-12-02
HRP20110555T1 (hr) 2011-09-30
PT2258345T (pt) 2017-01-20
ZA200801362B (en) 2009-03-25
CN1901884B (zh) 2012-07-25
DK2258346T3 (da) 2017-11-13
TWI342221B (en) 2011-05-21
DK1663183T3 (da) 2011-08-29
JP2018035163A (ja) 2018-03-08
EP2258344A2 (en) 2010-12-08
NZ545499A (en) 2009-11-27
PT1663183E (pt) 2011-08-25
EA033224B1 (ru) 2019-09-30
EP2258345B1 (en) 2016-09-21
ECSP066397A (es) 2006-08-30
NO20100367L (no) 2006-05-29
EA201890737A3 (ru) 2019-01-31
SG179401A1 (en) 2012-04-27
EP2258344B1 (en) 2012-11-14
JP2013241460A (ja) 2013-12-05
CR20120661A (es) 2013-03-13
NO20061342L (no) 2006-05-29
RS57663B1 (sr) 2018-11-30
KR101563222B1 (ko) 2015-10-26
PT2258346T (pt) 2017-10-24
JP2016094433A (ja) 2016-05-26
CN102772380A (zh) 2012-11-14
JP5498411B2 (ja) 2014-05-21
SI1663183T1 (sl) 2011-09-30
TW200522979A (en) 2005-07-16
SG145690A1 (en) 2008-09-29
CA2536638C (en) 2010-04-06
KR20060121837A (ko) 2006-11-29
CR20120662A (es) 2013-03-13
CY1111981T1 (el) 2015-11-04
JP2007504142A (ja) 2007-03-01
EP2258344A3 (en) 2011-01-19
EA200900292A1 (ru) 2009-06-30
HUE031153T2 (en) 2017-07-28
HK1094766A1 (en) 2007-04-13
SG10201507902UA (en) 2015-10-29
EP2258346A2 (en) 2010-12-08
JP5395125B2 (ja) 2014-01-22
EA011924B1 (ru) 2009-06-30
CN101919858A (zh) 2010-12-22
KR20140046078A (ko) 2014-04-17
HK1257502A1 (zh) 2019-10-25
CY1119651T1 (el) 2018-04-04
UA85564C2 (ru) 2009-02-10
PL1663183T3 (pl) 2011-10-31
AU2010238573A1 (en) 2010-11-18
PL2258346T3 (pl) 2018-01-31
ATE516017T1 (de) 2011-07-15
HK1145969A1 (en) 2011-05-13
WO2005039551A3 (en) 2006-08-03
ES2653762T3 (es) 2018-02-08
KR20110122771A (ko) 2011-11-10
ES2367173T3 (es) 2011-10-31
MXPA06002346A (es) 2006-05-19
AU2004283087C1 (en) 2008-04-24
CY1118505T1 (el) 2017-07-12
AU2007249115B2 (en) 2010-08-12
EA200600473A1 (ru) 2006-10-27
SI2258346T1 (sl) 2017-12-29
AU2004283087B2 (en) 2007-09-20
EP2258346B1 (en) 2017-09-27
EP2942051B1 (en) 2018-01-17
EP1663183B1 (en) 2011-07-13
NO334418B1 (no) 2014-03-03
CN1901884A (zh) 2007-01-24
WO2005039551A2 (en) 2005-05-06
CA2689639A1 (en) 2005-05-06
ME00130B (me) 2010-10-10
ZA200801361B (en) 2011-11-30
CR8256A (es) 2008-01-11
EA201301045A1 (ru) 2014-05-30
AU2010238573B2 (en) 2012-12-13
ES2399810T3 (es) 2013-04-03
HUE038792T2 (hu) 2018-11-28
AU2004283087A1 (en) 2005-05-06
RS20060140A (en) 2008-09-29
ES2608720T3 (es) 2017-04-12
US20050048112A1 (en) 2005-03-03
NO330282B1 (no) 2011-03-21
HK1217298A1 (zh) 2017-01-06
SI2258345T1 (sl) 2017-01-31
PL2258345T3 (pl) 2017-03-31
EP3354261A1 (en) 2018-08-01
CN101919858B (zh) 2013-10-30
CA2689639C (en) 2014-06-10
CN102764244A (zh) 2012-11-07
NO335326B1 (no) 2014-11-10
HUE035985T2 (hu) 2018-06-28
KR101281994B1 (ko) 2013-07-04
ES2666390T3 (es) 2018-05-04
DK2942051T3 (en) 2018-05-07
EP2258345A2 (en) 2010-12-08
IL173939A0 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
RS59969B1 (sr) Čvrsti farmaceutski dozni oblik